Sanofi, Lilly and Novo make cases for diabetes drugs at ADAThe American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and Share XSanofi, Lilly and Novo make cases for diabetes drugs at ADAhttps://pharmaphorum.com/news/sanofi-lilly-and-novo-diabetes/
Sanofi appoints former Novartis exec Hudson as CEOSanofi has appointed Novartis’ pharma chief Paul Hudson as chief executive to replace the retiring Olivier Brandicourt, prompting Share XSanofi appoints former Novartis exec Hudson as CEOhttps://pharmaphorum.com/news/sanofi-appoints-former-novartis-exec-hudson-as-ceo/
Sanofi names ex-Roche cancer guru Dietmar Berger as development leadRoche alumnus Dietmar Berger has joined Sanofi as head of development following a short stint in biotech. In Share XSanofi names ex-Roche cancer guru Dietmar Berger as development leadhttps://pharmaphorum.com/news/sanofi-names-ex-roche-cancer-guru-dietmar-berger-as-development-lead/
Lilly moves Crohn’s drug into phase 3, faces safety setback in JapanEli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, Share XLilly moves Crohn’s drug into phase 3, faces safety setback in Japanhttps://pharmaphorum.com/news/lilly-moves-crohns-drug-mirikizumab/
The Pharma Social Media ConferencePharma Social Media Share XThe Pharma Social Media Conferencehttps://pharmaphorum.com/events/the-pharma-social-media-conference/
Sanofi claims EU okay for Dupixent in asthmaSanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important Share XSanofi claims EU okay for Dupixent in asthmahttps://pharmaphorum.com/news/sanofi-claims-eu-okay-for-dupixent-in-asthma/
Cholesterol drug from Sanofi/Regeneron gains US CV risk reduction useSanofi and Regeneron’s Praluent cholesterol drug has been approved in the US to help prevent cardiovascular events, a Share XCholesterol drug from Sanofi/Regeneron gains US CV risk reduction usehttps://pharmaphorum.com/news/cholesterol-drug-from-sanofi-regeneron-gains-us-cv-risk-reduction-use/
Sanofi/Regeneron skin cancer drug among flurry of decisions from EU regulatorsA new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group Share XSanofi/Regeneron skin cancer drug among flurry of decisions from EU regulatorshttps://pharmaphorum.com/news/sanofi-regeneron-skin-cancer-drug-among-flurry-of-approvals-from-eu-regulators/
Sanofi Q1 growth driven by GenzymeGenzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, Share XSanofi Q1 growth driven by Genzymehttps://pharmaphorum.com/news/sanofi-q1-growth-driven-by-genzyme/
